Elevated Plasma Fibrinogen Rather Than Residual Platelet Reactivity After Clopidogrel Pre-Treatment Is Associated With an Increased Ischemic Risk During Elective Percutaneous Coronary Intervention
Lawrence Ang(University of California San Diego), Ehtisham Mahmud(Cardiovascular Institute of the South), Khalid Bin Thani(University of California San Diego), Manjusha Ilapakurti(University of California San Diego), Vachaspathi Palakodeti(University of California San Diego), Michael S. Lee(University of California, Los Angeles)
Cited by 39
Related Papers
Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic
|Journal of the American College of Cardiology|2020|415
Management of Acute Myocardial Infarction During the COVID-19 Pandemic
|Journal of the American College of Cardiology|2020|395
Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women
|Circulation|2020|310
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study
|Thrombosis Research|2006|225
The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention
|JACC: Cardiovascular Interventions|2018|213